Opening question: When a research-peptide listing flashes a CancerPPD hit, “anticancer peptide database” screenshot, or ACP-catalog badge, how do you tell curated anticancer-peptide database literacy apart from proof the vial treats cancer?
Short answer: open the live CancerPPD 2.0 repository (Raghava Lab, IIIT-Delhi)—the updated front end of the CancerPPD resource—and the founding methods paper, Tyagi et al., Nucleic Acids Research (2015) (DOI 10.1093/nar/gku892; PMID 25270878). CancerPPD / CancerPPD 2.0 compiles experimentally reported anticancer peptides and proteins with sequence, modification, assay, tissue/cell-line, and predicted-structure fields curated from literature and related sources. That is catalog literacy for published ACP records. It is not a clinical oncology indication, efficacy proof, or dosing review of a random research SKU.
A practical CancerPPD checklist when listings lean on ACP-database screenshots:
- Catalog hit ≠ medicine clearance: A matching CancerPPD entry documents that some published experiment reported anticancer activity for a related sequence under specific assay conditions. It does not prove the bottle in an ad is that material—or that it is an approved cancer drug.
- Database ≠ predictor: CancerPPD is a curated repository. AntiCP 2.0 and similar tools score sequences computationally. A listing that merges a database screenshot with a “predicted anticancer” badge without saying which claim is which is mixing evidence types.
- Assay and context fields matter: Browse/search facets include tissue, cell line, assay type, length, and modifications. Ads that hide those fields while waving a CancerPPD logo hide the claim.
- What to open next: If a listing implies a research peptide is “CancerPPD-approved for patients,” open CancerPPD 2.0 and Tyagi et al. and ask whether the claim teaches catalog literacy—or borrows oncology language for human-use meaning.
None of those steps turns a laboratory research listing into an approved medicine. Company research-only catalogs document laboratory intent and paperwork such as certificates of analysis; they do not create human-use approval. For company facts only—not clinical evidence—Apollo Peptides states products are for laboratory research only, not for human or veterinary use, and describes third-party testing with certificates of analysis.
Bottom line: Use CancerPPD / CancerPPD 2.0 to read experimentally reported ACP records honestly—what the entry actually curated, how that differs from a prediction score, and what a database badge does not prove about a vial—then notice whether the listing is teaching catalog literacy or dressing a research chemical with cancer-treatment art. That habit changes what you verify before trusting an ACP badge—it is not advice to buy, inject, or dose any peptide.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the CancerPPD 2.0 repository and Tyagi et al. Nucleic Acids Res. 2015 (DOI 10.1093/nar/gku892; PMID 25270878) (fetched 2026-10-04 PT). No invented studies, quotes, or dosing. Not medical or legal advice.
Sources
1. CancerPPD 2.0 — repository of anticancer peptides and proteins (Raghava Lab)
2. Tyagi et al., Nucleic Acids Res. 2015 (DOI 10.1093/nar/gku892)
3. PMID 25270878 — PubMed record for CancerPPD
4. Apollo Peptides (company facts only)
Related reading
AntiCP 2.0 scores are not research-peptide cancer clearance
APD literacy when peptide ads flash antimicrobial-peptide database screenshots
DBAASP literacy when peptide ads flash antimicrobial activity and structure records